The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|1|125-135

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.1, 2014-01, pp. : 125-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems

By  

Current Drug Targets, Vol. 16, Iss. 10, 2015-09 ,pp. : 1107-1132

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting mTOR Signaling Pathway in Ovarian Cancer

By  

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2960-2968

Bentham Science Publishers

Access to resources Recommend Favorite

An overview of the mTOR pathway as a target in cancer therapy

By Gentzler Ryan D   Altman Jessica K   Platanias Leonidas C  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 5, 2012-05 ,pp. : 481-489

Informa Healthcare

Access to resources Recommend Favorite

The mTOR Pathway: A New Target in Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. : 484-495

Bentham Science Publishers

Access to resources Recommend Favorite

Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 8, 2016-09 ,pp. : 945-955

Bentham Science Publishers

Access to resources Recommend Favorite